Two Sigma Investments
CAPR icon

Two Sigma Investments’s Capricor Therapeutics CAPR Stock Holding History

Two Sigma Investments’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$940K Sell
30,932
-23,841
-44% -$635K ﹤0.01% 3306
2025
Q4 		$1.58M Sell
54,773
-301,023
-85% -$3.93M ﹤0.01% 2612
2025
Q3 		$2.57M Buy
355,796
+199,959
+128% +$1.47M ﹤0.01% 1960
2025
Q2 		$1.55M Buy
155,837
+30,882
+25% +$326K ﹤0.01% 1998
2025
Q1 		$1.19M Buy
124,955
+5,908
+5% +$82K ﹤0.01% 2080
2024
Q4 		$1.64M Buy
119,047
+82,254
+224% +$1.44M ﹤0.01% 1852
2024
Q3 		$560K Buy
36,793
+12,882
+54% +$63.7K ﹤0.01% 2416
2024
Q2 		$114K Sell
23,911
-89
-0.4% -$496 ﹤0.01% 2806
2024
Q1 		$163K Buy
24,000
+4,300
+22% +$20.8K ﹤0.01% 2760
2023
Q4 		$96.3K Buy
+19,700
New +$64.1K ﹤0.01% 2942
2020
Q3 		– Sell
-43,407
Closed -$200K – 3114
2020
Q2 		$200K Buy
+43,407
New +$189K ﹤0.01% 2638
2020
Q1 		– Sell
-40,680
Closed -$52K – 3152
2019
Q4 		$52K Buy
+40,680
New +$83.9K ﹤0.01% 3568

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Two Sigma Investments's CAPR Position: Q1 2026 in Review

Two Sigma Investments reduced its Capricor Therapeutics (CAPR) stake by 44% in Q1 2026, selling an estimated $635K and leaving 30,932 shares worth $940K. The position accounts for ﹤0.01% of the portfolio, ranked #3306.

Two Sigma Investments first reported a position in CAPR in Q4 2019 and has held it in 12 quarters since. The position peaked at $2.57M in Q3 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Two Sigma Investments held 30,932 shares of Capricor Therapeutics worth $940K as of Q1 2026.
  • Two Sigma Investments sold 23,841 Capricor Therapeutics shares in Q1 2026, an estimated $635K.
  • Capricor Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3306 holding.
  • Two Sigma Investments first reported a position in Capricor Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • Two Sigma Investments's Capricor Therapeutics position peaked at $2.57M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.